SAN DIEGO, Dec. 31, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, and GATC Health Corp. (GATC), a tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, today announced a SPV transaction to advance ozuriftamab vedotin (Oz-V) (CAB-ROR2-ADC) in a Phase 3 Study in 2L+ oropharyngeal squamous cell carcinoma (OPSCC).

BioAtla, Inc. (NASDAQ: BCAB - Get Free Report) saw a significant decline in short interest during the month of December. As of December 15th, there was short interest totaling 4,341,741 shares, a decline of 29.9% from the November 30th total of 6,190,599 shares. Based on an average trading volume of 989,384 shares, the short-interest ratio is

Mirum Pharmaceuticals (NASDAQ: MIRM - Get Free Report) and BioAtla (NASDAQ: BCAB - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership. Institutional and Insider Ownership 77.2% of BioAtla shares are

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into Pre-paid Advance Agreements with an affiliate of Yorkville Advisors Global (Yorkville) and funds managed by of Anson Advisors Inc. to provide an aggregate $7.5 million advance to the Company. BioAtla also entered into a Standby Equity Purchase Agreement in which Yorkville has a commitment to buy, if the Company exercises its option, for up to a total of $15 million of common stock at a 3% discount to the then current market prices over three years, subject to certain conditions.

BioAtla, Inc. ( BCAB ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Jay Short - Co-Founder, CEO & Chairman Sheri Lydick - Chief Commercial Officer Eric Sievers - Chief Medical Officer Richard Waldron - Senior VP & CFO Conference Call Participants Julie Miller Yu He - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, everyone, and welcome to today's BioAtla Third Quarter 2025 Earnings Call.

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approval Company is in advanced stages to finalize a strategic transaction with a potential partner and we remain on track to complete the transaction by year end BA3182 trial in advanced adenocarcinomas is currently ongoing and evaluating various dosing and treatment schedules with a readout expected in the first half of 2026 Achieved milestone with Context Therapeutics under the license agreement for the CAB-Nectin4-TCE reflecting continued progress and validation of BioAtla's differentiated CAB T-cell engager platform Management to host a conference call and webcast today at 4:30 p.m. Eastern Time SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the third quarter ended September 30, 2025 and provided highlights on its clinical programs.

— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents

SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2025 and provide business highlights.

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced presentation of a poster entitled “Targeting HPV E6/E7 Upregulation of the Transmembrane Receptor Tyrosine Kinase ROR2 with the ADC Ozuriftamab Vedotin in Patients with Advanced HPV+ Oropharyngeal Squamous Cell Carcinoma” which details clinical data from its investigational antibody-drug conjugate (ADC), ozuriftamab vedotin (Oz-V), at the International Papillomavirus Society (IPVS) Conference, taking place October 23–26, 2025, in Bangkok, Thailand.

Adverse events (AEs) generally transient and readily manageable; only 2 cases of cytokine release syndrome (CRS) Prolonged tumor control with increasing doses of BA3182; confirmed partial response (cPR) at 0.6 mg in a patient with intrahepatic cholangiocarcinoma without progression for >6 months​ Maximally tolerated dose not yet defined; dose escalation continues; currently testing 1.8 mg dose level​ SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preliminary clinical data from a Phase 1 study of BA3182 during a poster presentation titled “Preliminary Results from a First-in-Human Phase 1 Study of BA3182, a Dual-Conditionally Binding Biologic (CAB) EpCAM x CD3 Bispecific T-cell Engager in Patients with Treatment Refractory Metastatic Adenocarcinoma” at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany. The poster was featured in the Investigational Immunotherapy session on Sunday, October 19.